Must Reads

Canadian Pharma: High Prices, Low Research & Development

The Globe’s Jeffrey Simpson has an excellent column on the state of big pharma in Canada, noting that Canadians pay high prices for pharmaceuticals but that big pharma has not met its commitment to devote 10 percent of sales to research and development.  Prices would increase further with potential legal reforms in the Canada – EU Trade Agreement.

Tags: / /

Comments are closed.